Dow Jones
39.287,24 +117,72 (+0,30%) Nasdaq
18.006,13 +126,84 (+0,71%) Nikkei 225
40.074,69 +443,63 (+1,12%) EUR/USD
1,0748 +0,0006 (+0,05%) Bitcoin EUR
57.671,62 -1.233,49 (-2,09%) CMC Crypto 200
1.334,66 -9,85 (-0,73%)
Merus N.V. (MRUS)
- GlobeNewswire
Merus Announces Business Update Conference Call
Zeno interim clinical data continues to show robust efficacy in NRG1+ NSCLC and PDAC: Sufficient clinical data expected in 1H24 to support potential BLA submissions Petosemtamab 2L+ HNSCC phase 3 trial design supported by INTERLINK-1 control armClinical data update on petosemtamab monotherapy in 2L+ HNSCC planned 2024MCLA-129 abstracts accepted at ESMO AsiaInvestor call on Monday, October 16 at 7:30 a.m. ET UTRECHT, The Netherlands and CAMBRIDGE, Mass., Oct. 15, 2023 (GLOBE NEWSWIRE) -- Merus N.
- GlobeNewswire
Merus Announces Abstracts Accepted for Presentation at the ESMO Asia Congress 2023
Mini Oral: MCLA-129 in combination with osimertinib in treatment naïve, and after progression on osimertinib, non-small cell lung cancer Poster: MCLA-129 in previously treated head & neck squamous cell carcinoma UTRECHT, The Netherlands and CAMBRIDGE, Mass., Oct. 06, 2023 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS) (Merus, the Company, we, or our), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics® and Triclonics®), today announced the acc
- GlobeNewswire
Merus to Participate in Upcoming Investor Conferences
UTRECHT, The Netherlands and CAMBRIDGE, Mass., Aug. 31, 2023 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics® and Triclonics®), today announced that Bill Lundberg, M.D., President, Chief Executive Officer of Merus, will participate in the following investor conferences: Citi's 2023 18th Annual BioPharma Conference (fireside chat): Thursday, September 7 at 2:40-3:25 p.m. ETMorgan Stanley 21st A
